Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead purchased 2,733 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was purchased at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the acquisition, the chief financial officer now owns 19,001 shares of the company’s stock, valued at approximately $344,108.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of ZYXI opened at $19.12 on Friday. The company has a market capitalization of $663.58 million, a price-to-earnings ratio of 86.91 and a beta of 1.05. The stock has a 50 day moving average of $23.36 and a 200 day moving average of $16.05. Zynex Inc. has a 12 month low of $7.51 and a 12 month high of $29.73.
Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $19.26 million during the quarter, compared to the consensus estimate of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. Sell-side analysts anticipate that Zynex Inc. will post 0.28 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Citigroup Inc. increased its position in Zynex by 310.6% in the fourth quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock worth $25,000 after buying an additional 2,398 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Zynex by 121.9% in the first quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock worth $54,000 after buying an additional 2,673 shares during the last quarter. Winslow Evans & Crocker Inc. purchased a new stake in Zynex in the second quarter worth $107,000. Cubist Systematic Strategies LLC purchased a new position in shares of Zynex in the fourth quarter valued at $111,000. Finally, Federated Hermes Inc. purchased a new position in shares of Zynex in the first quarter valued at $117,000. 0.05% of the stock is owned by institutional investors.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Story: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.